EEG Markers for ECT Response in Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
Single-center study to determine the relationship between changes in depression symptoms and electroencephalographic (EEG) patterns induced by electroconvulsive therapy (ECT)
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is Electroconvulsive Therapy (ECT) safe for humans?
How is electroconvulsive therapy (ECT) different from other treatments for depression?
Electroconvulsive therapy (ECT) is unique because it involves inducing controlled seizures in the brain to treat severe depression, which is different from medications or talk therapy. It is often used when other treatments have failed, and recent research suggests that EEG (a test that measures brain activity) can help predict which patients will respond well to ECT.46789
What data supports the effectiveness of this treatment for depression?
Who Is on the Research Team?
MohammadMehdi Kafashan
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults (18+) referred for ECT to treat resistant depression, including major depressive disorder with or without psychotic symptoms, and those with schizophrenia or schizoaffective disorder currently experiencing a depressed episode.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo up to 22 ECT sessions with EEG monitoring to assess depression severity and EEG markers
Follow-up
Participants are monitored for safety and effectiveness after ECT treatment
What Are the Treatments Tested in This Trial?
Interventions
- Electroconvulsive Therapy (ECT)
Electroconvulsive Therapy (ECT) is already approved in United States, European Union, Canada for the following indications:
- Severe depression
- Bipolar disorder
- Schizophrenia
- Catatonia
- Agitation in dementia (off-label)
- Severe depression
- Bipolar disorder
- Schizophrenia
- Catatonia
- Agitation in dementia (off-label)
- Severe depression
- Bipolar disorder
- Schizophrenia
- Catatonia
- Agitation in dementia (off-label)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor